US FDA knocks back Eisai's sedative Aquavan
This article was originally published in Scrip
Executive Summary
The US FDAhas deemedEisai's intravenous sedative-hypnotic agent Aquavan (fospropofol disodium injection) not approvable. However, the agency's rejection letter "outlines a pathway to potential approval" when used by appropriately trained physicians, the company said.